BDSX - CIK 0001439725
BIODESIX INC trades as BDSX. In its fiscal 2025 annual report the company posted revenue of $88.50M, up 24.1% from the prior year and net income of -$35.27M. This page tracks BIODESIX INC through 586 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years BIODESIX INC's revenue grew from $24.55M to $88.50M, a compound annual growth rate of 23.8%. Net profit margin expanded from -125.1% to -39.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Securities registration | S-3 | 2026-05-21 |
| Major company event | 8-K | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-28 |
| Annual report to shareholders | ARS | 2026-04-09 |
The largest companies sharing BIODESIX INC's SEC industry classification (services-medical laboratories).
BIODESIX INC reported revenue of $88.50M for fiscal year 2025, an increase of 24.1% year over year.
In its latest fiscal year BIODESIX INC reported a net loss of $35.27M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.